Kezar Life Sciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Kezar Life Sciences generated cash of -$81,645,000, which is less than the previous year. Cash used in financing activities reached the amount of $638,000 last year. Net change in cash is therefore -$4,963,000.
Cash Flow
| 2016 | -9.76M | -132K | 36K |
|---|---|---|---|
| 2017 | -8.10M | -389K | 49.75M |
| 2018 | -20.79M | -83.90M | 77.91M |
| 2019 | -29.87M | 20.41M | 272K |
| 2020 | -36.94M | -56.49M | 99.64M |
| 2021 | -42.43M | -28.44M | 112.58M |
| 2022 | -58.84M | -91.39M | 127.86M |
| 2023 | -81.64M | 76.04M | 638K |
KZR Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 40.45M | 62.88M | 21.22M | 14.95M | 24.18M | 51.04M | 9.76M | 19.76M |
Operating activities | ||||||||
Net income | -101.87M | -68.23M | -54.63M | -41.74M | -35.08M | -23.16M | -8.51M | -8.99M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 1.06M | 1.02M | 1.51M | 1.54M | 1.30M | 690K | 175K | 154K |
Stock-based compensation expense | 18.13M | 14.00M | 7.59M | 4.94M | 4.00M | 1.99M | 203K | 128K |
| Deferred income tax benefit | 18.13M | 14.00M | 7.59M | 4.94M | 4.00M | 1.99M | 203K | 128K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 6.34M | 1.81M | 1.21M | 313K | 2.20M | 1.44M | 81K | -469K |
Cash generated by operating activities | -81.64M | -58.84M | -42.43M | -36.94M | -29.87M | -20.79M | -8.10M | -9.76M |
Investing activities | ||||||||
Purchases Of Investments | -180.39M | -332.20M | -156.37M | -225.72M | -102.25M | -119.24M | 0 | 0 |
Investments In Property Plant And Equipment | -1.81M | -1.57M | -316K | -194K | -607K | -1.12M | -389K | -132K |
Acquisitions Net | 0 | 89.81K | 28.12K | 56.30K | -21.02K | 0 | 0 | 0 |
Cash generated by investing activities | 76.04M | -91.39M | -28.44M | -56.49M | 20.41M | -83.90M | -389K | -132K |
Financing activities | ||||||||
Common Stock Issued | 638K | 126.54M | 103.05M | 99.64M | 272K | 77.69M | 49.75M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -9.53M | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 638K | 127.86M | 112.58M | 99.64M | 272K | 77.91M | 49.75M | 36K |
Net Change In Cash | -4.96M | -22.42M | 41.65M | 6.27M | -9.23M | -26.86M | 41.28M | -10.00M |
Cash at end of period | 35.49M | 40.45M | 62.88M | 21.22M | 14.95M | 24.18M | 51.04M | 9.76M |
| Data source | Data source | Data source | Data source | Data source | Data source |